Morgan E Grams1,2,3, Adrienne Tin2,3, Casey M Rebholz2,3, Tariq Shafi4,2,3, Anna Köttgen2,5, Ronald D Perrone6, Mark J Sarnak6, Lesley A Inker6, Andrew S Levey6, Josef Coresh2,3. 1. Division of Nephrology, Department of Medicine, and mgrams2@jhmi.edu. 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 3. Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, Maryland. 4. Division of Nephrology, Department of Medicine, and. 5. Institute of Genetic Epidemiology, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany; and. 6. Division of Nephrology, Department of Medicine, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts.
Abstract
BACKGROUND AND OBJECTIVES: Causes of CKD differ in prognosis and treatment. Metabolomic indicators of CKD cause may provide clues regarding the different physiologic processes underlying CKD development and progression. DESIGN, SETTING, PARTICIPANTS & MEASUREMENTS: Metabolites were quantified from serum samples of participants in the Modification of Diet in Renal Disease (MDRD) Study, a randomized controlled trial of dietary protein restriction and BP control, using untargeted reverse phase ultraperformance liquid chromatography tandem mass spectrometry quantification. Known, nondrug metabolites (n=687) were log-transformed and analyzed to discover associations with CKD cause (polycystic kidney disease, glomerular disease, and other cause). Discovery was performed in Study B, a substudy of MDRD with low GFR (n=166), and replication was performed in Study A, a substudy of MDRD with higher GFR (n=423). RESULTS: Overall in MDRD, average participant age was 51 years and 61% were men. In the discovery study (Study B), 29% of participants had polycystic kidney disease, 28% had glomerular disease, and 43% had CKD of another cause; in the replication study (Study A), the percentages were 28%, 24%, and 48%, respectively. In the discovery analysis, adjusted for demographics, randomization group, body mass index, hypertensive medications, measured GFR, log-transformed proteinuria, and estimated protein intake, seven metabolites (16-hydroxypalmitate, kynurenate, homovanillate sulfate, N2,N2-dimethylguanosine, hippurate, homocitrulline, and 1,5-anhydroglucitol) were associated with CKD cause after correction for multiple comparisons (P<0.0008). Five of these metabolite associations (16-hydroxypalmitate, kynurenate, homovanillate sulfate, N2,N2-dimethylguanosine, and hippurate) were replicated in Study A (P<0.007), with all replicated metabolites exhibiting higher levels in polycystic kidney disease and lower levels in glomerular disease compared with CKD of other causes. CONCLUSIONS: Metabolomic profiling identified several metabolites strongly associated with cause of CKD.
RCT Entities:
BACKGROUND AND OBJECTIVES: Causes of CKD differ in prognosis and treatment. Metabolomic indicators of CKD cause may provide clues regarding the different physiologic processes underlying CKD development and progression. DESIGN, SETTING, PARTICIPANTS & MEASUREMENTS: Metabolites were quantified from serum samples of participants in the Modification of Diet in Renal Disease (MDRD) Study, a randomized controlled trial of dietary protein restriction and BP control, using untargeted reverse phase ultraperformance liquid chromatography tandem mass spectrometry quantification. Known, nondrug metabolites (n=687) were log-transformed and analyzed to discover associations with CKD cause (polycystic kidney disease, glomerular disease, and other cause). Discovery was performed in Study B, a substudy of MDRD with low GFR (n=166), and replication was performed in Study A, a substudy of MDRD with higher GFR (n=423). RESULTS: Overall in MDRD, average participant age was 51 years and 61% were men. In the discovery study (Study B), 29% of participants had polycystic kidney disease, 28% had glomerular disease, and 43% had CKD of another cause; in the replication study (Study A), the percentages were 28%, 24%, and 48%, respectively. In the discovery analysis, adjusted for demographics, randomization group, body mass index, hypertensive medications, measured GFR, log-transformed proteinuria, and estimated protein intake, seven metabolites (16-hydroxypalmitate, kynurenate, homovanillate sulfate, N2,N2-dimethylguanosine, hippurate, homocitrulline, and 1,5-anhydroglucitol) were associated with CKD cause after correction for multiple comparisons (P<0.0008). Five of these metabolite associations (16-hydroxypalmitate, kynurenate, homovanillate sulfate, N2,N2-dimethylguanosine, and hippurate) were replicated in Study A (P<0.007), with all replicated metabolites exhibiting higher levels in polycystic kidney disease and lower levels in glomerular disease compared with CKD of other causes. CONCLUSIONS: Metabolomic profiling identified several metabolites strongly associated with cause of CKD.
Authors: Craig S Wong; Christopher B Pierce; Stephen R Cole; Bradley A Warady; Robert H K Mak; Nadine M Benador; Fredrick Kaskel; Susan L Furth; George J Schwartz Journal: Clin J Am Soc Nephrol Date: 2009-03-18 Impact factor: 8.237
Authors: Hannah J Lees; Jonathan R Swann; Ian D Wilson; Jeremy K Nicholson; Elaine Holmes Journal: J Proteome Res Date: 2013-03-06 Impact factor: 4.466
Authors: Jiun-Ruey Hu; Josef Coresh; Lesley A Inker; Andrew S Levey; Zihe Zheng; Casey M Rebholz; Adrienne Tin; Lawrence J Appel; Jingsha Chen; Mark J Sarnak; Morgan E Grams Journal: Kidney Int Date: 2018-06-02 Impact factor: 10.612
Authors: Izabela Zakrocka; Katarzyna M Targowska-Duda; Artur Wnorowski; Tomasz Kocki; Krzysztof Jóźwiak; Waldemar A Turski Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2018-10-29 Impact factor: 3.000
Authors: Ke Wang; Leila R Zelnick; Yan Chen; Andrew N Hoofnagle; Terry Watnick; Stephen Seliger; Bryan Kestenbaum Journal: Clin J Am Soc Nephrol Date: 2019-10-18 Impact factor: 8.237